Amicus Therapeutics Inc. (NASDAQ:FOLD) finished Tuesday with an addition of $0.83 to close at $10.93, an upside of 8.22 percent. An average of 3,964,580 shares of common stock have been traded in the last five days. There was a gain of $1.27 in the past week. The last 20 days have seen an average of 3,080,255 shares traded, while the 50-day average volume stands at 2,385,404.
FOLD stock has decreased by -3.95% in the last month. The company shares reached their 1-month lowest point of $9.41 on 10/01/21. With the stock rallying to its 52-week high on 01/06/21, shares of the company touched a low of $8.60 and a high of $25.39 in 52 weeks. In spite of this, the price is down -56.95% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
6 days have passed since Amicus Therapeutics Inc. (FOLD) last reported insider trading activity. Crowley John F, who is Chairman & CEO, most recently acquired $7,500 shares at $10.00 per share on Oct 01. In this transaction, the insider spent $75,000. Chief Operating Officer, Campbell Bradley L, disposed of 10,515 shares at a price of $10.00 on Oct 01. The insider now owns more than $105,150 worth of shares. Prior to that, Chairman & CEO Crowley John F went on to Sale 22,000 shares at $11.08 each on Sep 15. An amount of $243,828 was transacted.
Amicus Therapeutics Inc. (FOLD) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 31.71 for the sector. This means investors are optimistic about the stock’s future prospects. The stock’s beta is 1.18. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.72, the price-to-book (PB) ratio at 13.66.
The quick ratio of Amicus Therapeutics Inc. for the three months ended June 29 was 4.10, and the current ratio was 4.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.83 and a total debt to equity ratio of 1.83 for the quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 88.40% against a 5-year average of 85.3%. Amicus Therapeutics Inc.’s EBITDA margin for the year ending June 29 is -90.08%, while its operating margin for the same period stands at -76.90%. Its gross profit as reported stood at $229.84 million compared to revenue of $260.89 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Amicus Therapeutics Inc.’s return on assets was -29.80%, compared to -35.9% over the last five years. In the past year, the return on investment has been -38.00%, and the 5-year average is -48.5%. Meanwhile, the return on equity (ROE) for the past 12 months has been -94.20% and the 5-year average holds at -79.2%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Amicus Therapeutics Inc. had $206.53 million in cash. The analyst consensus anticipated Amicus Therapeutics Inc.’s latest quarter earnings to come in at -$0.22 per share, but it turned out to be -$0.19, a 13.60% surprise. For the quarter, EBITDA amounted to -$36.62 million. Shareholders own equity worth $266.56 million.
From a technical analysis perspective, let’s take a brief look at Amicus Therapeutics Inc. (FOLD) price momentum. RSI 9-day as of the close on 05 October was 57.46%, suggesting the stock is Neutral, with historical volatility in this time frame at 72.75%.
As of today, FOLD’s price is $10.12 +13.15% or $1.27 from its 5-day moving average. FOLD is currently trading -4.04% lower than its 20-day SMA and +15.17% higher than its 100-day SMA. However, the stock’s current price level is +23.78% above the SMA50 and -54.40% below the SMA200.
The stochastic %K and %D were 47.49% and 33.81%, respectively, and the average true range (ATR) was 0.61. With the 14-day stochastic at 82.65% and the average true range at 0.55, the RSI (14) stands at 54.30%. The stock has reached 0.06 on the 9-day MACD Oscillator while the 14-day reading was at -0.21.
JP Morgan upgraded Amicus Therapeutics Inc. (NASDAQ: FOLD) to a an Overweight rating in its most recent analyst report. Previously, the stock was rated as a a Neutral.The consensus rating for Amicus Therapeutics Inc. (FOLD) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell FOLD, while 5 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 6 others rate it as a “buy”.
What is FOLD’s price target for the next 12 months?
Analysts predict a range of price targets between $12.00 and $29.00, with a median target of $16.00. Taking a look at these predictions, the average price target given by analysts for Amicus Therapeutics Inc. (FOLD) stock is $16.89.